Improved Efficacy WIth Nivolumab Plus Ipilimumab in Patients With Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Survival Outcomes and Independent Response Assessment With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma: 42-Month Follow-Up of a Randomized Phase 3 Clinical Trial
J Immunother Cancer 2020 Jul 01;8(2)e000891, RJ Motzer, B Escudier, DF McDermott, O Arén Frontera, B Melichar, T Powles, F Donskov, ER Plimack, P Barthélémy, HJ Hammers, S George, V Grünwald, C Porta, V Neiman, A Ravaud, TK Choueiri, BI Rini, P Salman, CK Kollmannsberger, SS Tykodi, MO Grimm, H Gurney, R Leibowitz-Amit, PF Geertsen, A Amin, Y Tomita, MB McHenry, SS Saggi, NM TannirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.